Innovent Biologics, Inc. (IVBXF) Stock

About Innovent Biologics, Inc.

Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011. It specializes in the discovery, advancement, and production of antibody-based drug candidates, with a strategic focus on therapeutic areas including cancer treatment (oncology), eye conditions (ophthalmology), immune system disorders (immunology), and metabolic ailments. Innovent's flagship therapeutic offering is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in managing various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Additionally, its portfolio includes several other approved treatments: Byvasda, for diverse malignant tumors; Halpryza, addressing non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with advanced or metastatic cholangiocarcinoma; Olverembatinib, developed for adult patients requiring tyrosine kinase inhibitor treatment; and Cyramza, which targets four distinct cancer types. Beyond its commercialized products, Innovent maintains a robust pipeline of investigational therapies. These include IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody designed to combat hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody being explored for liver cancer and renal cell carcinoma. The company is also advancing IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy targeting relapsed or refractory multiple myeloma in adults; IBI-376, for recurrent or refractory follicular lymphoma; and IBI-112, designated for psoriasis. Moreover, Innovent provides pharmaceutical product distribution services, alongside offering expert consultation and engaging in research and development activities. Its operational strategy is further bolstered by strategic alliances with partners such as NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.

Innovent Biologics, Inc. is headquartered in CN.

Innovent Biologics, Inc. (IVBXF) stock trades at $12.80 with a market capitalization of $22.28B. The stock is valued at a price-to-earnings (P/E) ratio of 159.93, price-to-book of 7.04, price-to-sales of 10.63. Over the past 52 weeks the stock has ranged between $9.10 and $15.12, and currently trades 15.3% below its 52-week high.

On profitability, Innovent Biologics, Inc. generates a return on equity (ROE) of 4.82%, return on capital employed of 2.53%, an operating margin of 5.63%, a net profit margin of 6.24%.

In its most recent fiscal year, Innovent Biologics, Inc. reported annual revenue of $12.7B, net profit of $793.0M, revenue has compounded at 27.0% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 0.15 — a conservative balance sheet with little leverage risk, a current ratio of 2.62, total assets of $37.4B, $17.4B in cash and equivalents.

IVBXF has an average daily trading volume of 3,963 shares, a beta of 0.20 (less volatile than the overall market).

Official website: www.innoventbio.com